Science & Enterprise subscription

Follow us on Twitter

  • New post on Science and Enterprise: Editorial Posts Resume Tomorrow https://t.co/ZTVMsYlwg8 #Science #Business
    about 6 hours ago
  • As mobile phones, smart watches, and tablets play an increasingly key role in our daily lives, a new report shows m… https://t.co/HNOl3qa4oI
    about 2 days ago
  • New post on Science and Enterprise: Infographic – Mobile Industry’s Economic Role https://t.co/aMBZtn0gkM #Science #Business
    about 2 days ago
  • FDA expert panel gives thumbs-up to Aimmune’s peanut allergy drug https://t.co/srCucGLuB5
    about 3 days ago
  • A developer of a drug for migraine formulated as a dry powder and given as a nasal spray is raising $82.5 million i… https://t.co/gn4NSNTmBR
    about 3 days ago

Please share Science & Enterprise

A.I., Robotics Studied for Military Trauma System

Medevac training in Afghanistan

Medical and robotics labs at two universities in Pittsburgh are developing a portable, autonomous trauma care device to stabilize wounded military service people in the field. . . . → Read More: A.I., Robotics Studied for Military Trauma System

Platform to Integrate Robotics, Synthetic Biology, A.I.

Microbes

Two companies are developing a new model for a cloud-based platform that makes possible automated collaborative research with artificial intelligence in synthetic biology. . . . → Read More: Platform to Integrate Robotics, Synthetic Biology, A.I.

Zika Vaccine Clinical Trial Underway

The first of a series of clinical trials testing inactivated Zika particles as a vaccine to protect against the live Zika virus is recruiting participants. . . . → Read More: Zika Vaccine Clinical Trial Underway

Health Agency Funds Drug-Resistant Bacteria R&D

Biomedical Advanced Research and Development Authority, or BARDA, signed agreements worth $67 million to develop new treatments and diagnostics for urgent drug-resistant infections. . . . → Read More: Health Agency Funds Drug-Resistant Bacteria R&D

Influenza A Therapy Shown Working in Trial

Electron-microscope image of the 2009 H1N1 influenza virus (CDC.gov)

5 October 2015. A clinical trial testing a synthetic antibody designed to treat influenza A shows the treatment is effective in reducing the spread of flu viruses in humans. Visterra Inc., the therapy’s designer, also received a contract valued as much as $204.5 million . . . → Read More: Influenza A Therapy Shown Working in Trial

Regeneron to Develop Antibody Therapy for Ebola

Scanning electron micrograph shows Ebola virus budding on monkey kidney cells (Defense.gov)

21 September 2015. Regeneron Pharmaceuticals Inc. received a contract from the U.S. Department of Health and Human Services to develop an engineered antibody designed to treat Ebola infections. The initial $17 million contract from HHS’s Biomedical Advanced Research and Development Authority . . . → Read More: Regeneron to Develop Antibody Therapy for Ebola

Ebola-Marburg Vaccine Development, Testing Contract Awarded

Ebola health care workers in Guinea (European Commission-ECHO/USIAD)

31 October 2014. A biodefense unit of the U.S. Department of Defense awarded a contract to vaccine maker Profectus BioSciences Inc. for development and testing of a vaccine protecting against the two major Ebola strains and related Marburg viruses. The $9.5 million contract with the . . . → Read More: Ebola-Marburg Vaccine Development, Testing Contract Awarded

Clinical Trial to Test Safety of MRSA Drug Candidate

Scanning electron micrograph image of MRSA bacteria (Janice Haney Carr, Centers for Disease Control and Prevention)

Enanta Pharmaceuticals, a biotechnology company in Watertown, Massachusetts, is starting an early-stage clinical trial of an antibiotic to treat methicillin-resistant Staphylococcus aureus or MRSA infections. The drug, code-named EDP-788, is being developed under a contract with National . . . → Read More: Clinical Trial to Test Safety of MRSA Drug Candidate

NIH Funding Further Marburg Virus Therapy Development

Marburg virus (U.S. Centers for Disease Control and Prevention)

BioCryst Pharmaceuticals Inc., a developer of drugs for infectious and rare diseases in Durham, North Carolina, says National Institutes of Health (NIH) is continuing its contract with the company to develop a treatment for Marburg virus, the cause of a rare but dangerous tropical . . . → Read More: NIH Funding Further Marburg Virus Therapy Development

Contract Awarded for Influenza Vaccine and Immune Booster

H1N1 virus (U.S. Centers for Disease Control)

NanoBio Corporation in Ann Arbor, Michigan received a new contract from National Institute of Allergy and Infectious Diseases, part of National Institutes of Health, for development of a pandemic influenza vaccine and adjuvant to boost the immune response of that vaccine. The initial contract value is . . . → Read More: Contract Awarded for Influenza Vaccine and Immune Booster